MedTrace Logo

Letrozole for Lymphangioleiomyomatosis

NCT01353209 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2024-04-17

Study results available
· View outcomes & findings →

Summary

The hypothesis in this study is that estrogen suppression by an aromatase inhibitor in postmenopausal women with lymphangioleiomyomatosis (LAM) will prevent or delay progression of lung disease and result in a decrease in the rate of decline in FEV1

Conditions

  • Lymphangioleiomyomatosis

Interventions

DRUG

Letrozole

2.5 mg daily for twelve months

DRUG

Placebo

placebo given daily for twelve months

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Francis X McCormack, MD · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2014-09-30
Completion
2014-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01353209 on ClinicalTrials.gov